Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound

After natalizumab (NAT) cessation, some multiple sclerosis (MS) patients experience a severe disease rebound. The rebound pathophysiology is still unclear; however, it has been linked to interleukin-17-producing T-helper (Th17) cells. We demonstrate that during NAT treatment, MCAM+CCR6+Th17 cells gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Janoschka, Claudia, Lindner, Maren, Koppers, Nils, Starost, Laura, Liebmann, Marie, Eschborn, Melanie, Schneider-Hohendorf, Tilman, Windener, Farina, Schafflick, David, Fleck, Ann-Katrin, Koch, Kathrin, Deffner, Marie, Schwarze, Anna-Sophie, Schulte-Mecklenbeck, Andreas, Metz, Imke, Meuth, Sven G., Gross, Catharina C., Meyer zu Hörste, Gerd, Schwab, Nicholas, Kuhlmann, Tanja, Wiendl, Heinz, Stoll, Monika, Klotz, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910615/
https://www.ncbi.nlm.nih.gov/pubmed/36574650
http://dx.doi.org/10.1073/pnas.2209944120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910615/
https://www.ncbi.nlm.nih.gov/pubmed/36574650
http://dx.doi.org/10.1073/pnas.2209944120

Ejemplares similares